KIT and gastrointestinal stromal tumor: Specifically, avapritinib6 (formerly BLU-285, Blueprint Medicines Corporation), the only selective and potent inhibitor of mutant KIT and PDGFRA kinases, targeting D842V, has received approval for the treatment of patients with unresectable and metastatic GIST by both the United States Food and Drug Administration (FDA) (PDGFRA exon 18 mutation subpopulation) and the EMA (only in patients with the D842V mutation in exon 18 of PDGFRA).